The influence of serum cholinesterase levels and sarcopenia on postoperative infectious complications in colorectal cancer surgery

Takano, Yasuhiro; Haruki, Koichiro; Kai, Wataru; Tsukihara, Shu; Yasunobu, Kobayashi; Ito, Daisuke; Kanno, Hironori; Son, Kyonsu; Hanyu, Nobuyoshi; Eto, Ken

doi:10.1007/s00595-022-02625-1

Cited by 4 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of note, canonical correlation analysis con rmed that CHE had a robust correlation with nutrition-related indicators (total protein, albumin, hemoglobin and BMI) in our study. Importantly, a combined assessment of serum cholinesterase and albumin levels can serve as nutrition-related serum markers and be successfully employed to predict prognosis in cancer patients [11,25] . In addition, cancer patients with poorer nutritional status are less likely to complete oncologic treatment according to plan and are at a high risk of developing adverse outcomes.…”

Section: Discussionmentioning

confidence: 99%

Baseline Serum Cholinesterase Levels Predict the Outcome of HIV-Related Diffuse Large B-Cell Lymphoma

Zhou,

Qin,

Tong

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Serum cholinesterase (CHE) has been utilized as a surrogate marker in the context of solid cancers. Nevertheless, its potential association with the prognosis of hematologic malignancies remains unclear. Methods Sixty-five patients with new-onset HIV-related diffuse large B-cell lymphoma (DLBCL) were enrolled in this retrospective study. The patients were categorized into a high CHE group (> 5500 U/L) and a low CHE group (≤ 5500 U/L). The demographic details, laboratory test results and clinical outcomes were compared between the high CHE group and the low CHE group. The overall response rate (ORR) at the end of chemotherapy was assessed by logistic regression analysis, and the 1-year overall survival rate (OS) was assessed by a multivariate Cox proportional hazards model. Results Compared with patients with high CHE, HIV-related DLBCL patients with low CHE exhibited lower levels of hemoglobin [g/L; 101.0 (81.0-115.0) vs. 123.5 (108.2–141.0), P < 0.001] and serum albumin [g/L; 31.2 ± 5.6 vs. 40.4 ± 4.5, P < 0.001] but higher levels of lactate dehydrogenase (LDH) [U/L; 404.0 (253.0-849.0) vs. 248.0 (178.3–372.0), P = 0.014] and C-reactive protein (CRP) [mg/L; 36.1 (5.8–66.6) vs. 5.1 (0.8–5.1), P < 0.001]. Moreover, HIV-related DLBCL patients with low CHE demonstrated a higher prevalence of Ann Arbor stage III/IV (92.6% vs. 56.8%, P < 0.001) and International Prognostic Index (IPI) ≥ 3 (85.2% vs. 35.1%, P = 0.002) at the time of diagnosis of DLBCL. The 1-year OS of patients was 84.2% in the high CHE group and 40.7% in the low CHE group (log-rank P < 0.001). At the end of chemotherapy, the ORR was 80.0% in the high CHE group and 31.8% in the low CHE group (P < 0.001). In multivariate analysis, CHE > 5500 U/L was independently associated with a higher ORR [adjusted odds ratio (AOR): 4.74 (1.02–22.06), P = 0.047] and lower 1-year mortality [hazard ratio (HR): 0.11 (0.03–0.52), P = 0.005]. Conclusion Based on our robust data, baseline serum CHE levels show great potential as a surrogate marker for risk stratification and for guiding treatment decisions in HIV-related DLBCL patients.

show abstract

Section: Discussionmentioning

confidence: 99%